US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ensysce Biosciences Inc.

2.05

-0.0400-1.91%

Post-market: 2.060.0099+0.48%19:59 EDT

Volume:438.22K

Turnover:905.35K

Market Cap:4.86M

PE:-0.18

High:2.18

Open:2.06

Low:1.98

Close:2.09

Loading ...

Overview Company News Filings

Ensysce Biosciences Secures FDA Breakthrough Therapy Designation and Advances Regulatory Review for Opioid with Overdose Protection, Supported by NIDA Grants

Ensysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies

Ensysce Biosciences initiates Phase 3 study of PF614

Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk

Ensysce Biosciences Inc. Unveils Presentation on Groundbreaking Opioid Innovations and Clinical Advancements

Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development

Ensysce Biosciences Inc. Announces Symposium on Innovative Pain Management at PAINWeek 2025

Ensysce Biosciences Inc. Announces Change in Auditors Following Moss Adams and Baker Tilly Merger

Ensysce Biosciences Secures $5.3 Million NIDA Grant to Advance Overdose-Protective Opioid PF614-MPAR Toward Commercialization

Ensysce Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Ensysce Biosciences Shares Jump After Receiving Patent, Reporting 1Q Results

Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY

Ensysce Biosciences files to sell 1.3M shares of common stock for holders

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

ACCESS Newswire

Crude Oil Falls Over 3%; Philip Morris Earnings Top Views

Ensysce Biosciences Gets US Patent for Opioid Use Disorder Treatment; Shares Rise Pre-Bell

MT Newswires Live

Ensysce Biosciences receives U.S. patent for OUD treatment

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

ACCESS Newswire

Ensysce Biosciences files to sell 652,439 shares of common Stock for holders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ENSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENSC\",,,,,undefined,":{"symbol":"ENSC","market":"US","secType":"STK","nameCN":"Ensysce Biosciences Inc.","latestPrice":2.05,"timestamp":1754078400000,"preClose":2.09,"halted":0,"volume":438215,"hourTrading":{"tag":"盘后","latestPrice":2.0599,"preClose":2.05,"latestTime":"19:59 EDT","volume":13891,"amount":28258.2147,"timestamp":1754092790344},"delay":0,"floatShares":1787300,"shares":2370698,"eps":-11.448165,"marketStatus":"Closed","change":-0.04,"latestTime":"08-01 16:00:00 EDT","open":2.06,"high":2.175,"low":1.9797,"amount":905349.8674605,"amplitude":0.093445,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-11.448165,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754294400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":2.09,"preHourTrading":{"tag":"盘前","latestPrice":2.05,"preClose":2.09,"latestTime":"09:28 EDT","volume":69094,"amount":139385.8550404,"timestamp":1754054921607},"postHourTrading":{"tag":"盘后","latestPrice":2.0599,"preClose":2.05,"latestTime":"19:59 EDT","volume":13891,"amount":28258.2147,"timestamp":1754092790344},"volumeRatio":0.143475,"impliedVol":3.1521,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENSC\",,,,,undefined,":{"symbol":"ENSC","floatShares":1787300,"roa":"-88.46%","roe":"-221.97%","lyrEps":-11.448165,"volumeRatio":0.143475,"shares":2370698,"dividePrice":0,"high":2.175,"amplitude":0.093445,"preClose":2.09,"low":1.9797,"week52Low":1.62,"pbRate":"1.59","psRate":"0.78","week52High":14.67,"institutionHeld":0,"latestPrice":2.05,"eps":-11.448165,"divideRate":0,"volume":438215,"delay":0,"ttmEps":-11.448165,"open":2.06,"prevYearClose":8.14,"prevWeekClose":2.24,"prevMonthClose":2.09,"prevQuarterClose":2.23,"fiveDayClose":2.24,"twentyDayClose":2.31,"sixtyDayClose":2.17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555683889","title":"Ensysce Biosciences Secures FDA Breakthrough Therapy Designation and Advances Regulatory Review for Opioid with Overdose Protection, Supported by NIDA Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2555683889","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555683889?lang=en_us&edition=fundamental","pubTime":"2025-07-31 20:05","pubTimestamp":1753963532,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Secures FDA Breakthrough Therapy Designation and Advances Regulatory Review for Opioid with Overdose Protection, Supported by NIDA Grants. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on July 31, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL94B9q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2552462078","title":"Ensysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2552462078","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552462078?lang=en_us&edition=fundamental","pubTime":"2025-07-18 19:49","pubTimestamp":1752839355,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies. Ensysce Biosciences Inc., a clinical-stage company specializing in the development of next-generation opioids, has released an investor presentation highlighting their innovative approach to analgesia. The company focuses on targeted therapy areas with blockbuster potential, utilizing transformative trypsin-controlled chemistry. Key highlights include the upcoming launch of the lead product, which has demonstrated both safety and efficacy, and a shortened development timeline through the 505 regulatory pathway. Ensysce showcases two core technology platforms, TAAPTM for anti-abuse chemistry and MPAR for overdose protection, to enhance drug performance. The company emphasizes its strong global patent estate and experienced management team. You can access the full presentation through the link below.Disclaimer: This news brief was created by Publ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL5Vrn40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2551128966","title":"Ensysce Biosciences initiates Phase 3 study of PF614","url":"https://stock-news.laohu8.com/highlight/detail?id=2551128966","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551128966?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:16","pubTimestamp":1752668168,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (ENSC) announced the initiation of its pivotal Phase 3 study of PF614, the Company’s lead product candidate. This study, PF614-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-initiates-phase-3-study-of-pf614-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-initiates-phase-3-study-of-pf614-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2551140713","title":"Ensysce Biosciences Launches Pivotal Phase 3 Study of PF614, Aiming to Redefine Pain Therapy with Reduced Abuse Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2551140713","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551140713?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:00","pubTimestamp":1752667233,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the commencement of a pivotal Phase 3 study for its lead product candidate, PF614. This next-generation opioid is designed to provide effective pain relief while minimizing the risk of abuse. The study, titled PF614-301, is a multicenter, randomized, double-blind, placebo- and active-controlled trial aimed at evaluating the efficacy and safety of PF614 in treating moderate to severe pain following abdominoplasty surgery. Ensysce has partnered with Rho, Inc., a Clinical Research Organization with expertise in CNS disorders and pain studies, to conduct this trial. The results of this study are yet to be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL8pFzLV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2550662200","title":"Ensysce Biosciences Inc. Unveils Presentation on Groundbreaking Opioid Innovations and Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2550662200","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550662200?lang=en_us&edition=fundamental","pubTime":"2025-07-11 00:21","pubTimestamp":1752164509,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Inc., a clinical-stage company, has released a presentation detailing its advancements in developing 'Next Generation' opioid products. The company is leveraging two core technology platforms, TAAPTM  and MPAR , to enhance drug performance and address severe pain, particularly in cancer patients. Ensysce's lead product is nearing launch, boasting demonstrated safety and efficacy, and benefits from a shortened development timeline through the 505 regulatory pathway. The company emphasizes its strong global patent estate and experienced management team. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content use","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDL75jZ6s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2545284760","title":"Ensysce Biosciences Fully Enrolls Part 2 of PF614-MPAR-102 Study, Advancing Overdose-Protected Opioid Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2545284760","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545284760?lang=en_us&edition=fundamental","pubTime":"2025-06-24 20:05","pubTimestamp":1750766737,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Inc., a clinical-stage pharmaceutical company, has announced the full enrollment of Part 2 of the PF614-MPAR-102 clinical study. This phase of the study aims to examine the effect of food on the company's MPAR technology, which is designed to enhance opioid safety. The PF614-MPAR, which has been awarded the FDA's Breakthrough Therapy designation, incorporates Ensysce's proprietary TAAP and MPAR technologies to provide overdose protection while maintaining pain relief efficacy. The study is supported by a three-year grant from the National Institute on Drug Abuse, with funding secured through May 2027. Results of this clinical trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL6N5K0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2542581282","title":"Ensysce Biosciences Inc. Announces Symposium on Innovative Pain Management at PAINWeek 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2542581282","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542581282?lang=en_us&edition=fundamental","pubTime":"2025-06-11 20:12","pubTimestamp":1749643934,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Inc., a clinical-stage pharmaceutical company focused on innovative solutions for severe pain relief, will participate in PAINWeek 2025, the world's largest pain conference. The event will be held in Las Vegas on September 3rd, 2025. Ensysce will host a symposium titled 'Pain Management, RE-Invented: A New Era for Analgesia,' featuring discussions on the clinical challenges of today's pain landscape and new therapeutic approaches. The event will spotlight Ensysce's breakthrough TAAP and MPAR technologies, designed to reduce opioid misuse, abuse, and overdose while maintaining effective pain relief.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL96LJrX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2541006717","title":"Ensysce Biosciences Inc. Announces Change in Auditors Following Moss Adams and Baker Tilly Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2541006717","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541006717?lang=en_us&edition=fundamental","pubTime":"2025-06-06 05:03","pubTimestamp":1749157414,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Inc. recently announced a change in their certifying accountants following a merger between Moss Adams LLP, their former independent registered public accounting firm, and Baker Tilly US, LLP. Effective June 3, 2025, Baker Tilly will serve as the company's new independent registered public accounting firm. The transition comes after Moss Adams resigned due to the merger. The company confirmed no disagreements or reportable events with Moss Adams during the audit periods ending December 31, 2024, and 2023, nor in the interim period leading up to the change. Moss Adams has provided a letter to the Securities and Exchange Commission, agreeing with Ensysce's statements regarding the transition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDLCMFbr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2540630420","title":"Ensysce Biosciences Secures $5.3 Million NIDA Grant to Advance Overdose-Protective Opioid PF614-MPAR Toward Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2540630420","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540630420?lang=en_us&edition=fundamental","pubTime":"2025-06-04 20:11","pubTimestamp":1749039095,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Secures $5.3 Million NIDA Grant to Advance Overdose-Protective Opioid PF614-MPAR Toward Commercialization. Ensysce Biosciences Inc., a clinical-stage pharmaceutical company focused on developing innovative pain relief solutions, announced it has received a $5.3 million installment as part of a $15 million, three-year grant from the National Institute on Drug Abuse . This funding will accelerate the development of PF614-MPAR, a next-generation opioid designed to reduce the risk of overdose while providing effective pain relief. This product has earned FDA Breakthrough Therapy designation, acknowledging its potential impact on pain management. The grant is solely awarded to Ensysce Biosciences, supporting the company's mission to deliver safer opioid alternatives and advance toward commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9rpC4S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2535318037","title":"Ensysce Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535318037","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535318037?lang=en_us&edition=fundamental","pubTime":"2025-05-16 21:31","pubTimestamp":1747402309,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Inc reports results for the quarter ended March 31 - Earnings SummaryEnsysce Biosciences Inc ENSC.OQ reported a quarterly adjusted loss of $1.39 per share for the quarter ended Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nL8N3RO12L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC"],"gpt_icon":0},{"id":"2535036728","title":"Ensysce Biosciences Shares Jump After Receiving Patent, Reporting 1Q Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535036728","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535036728?lang=en_us&edition=fundamental","pubTime":"2025-05-14 06:48","pubTimestamp":1747176480,"startTime":"0","endTime":"0","summary":"Shares of Ensysce Biosciences climbed after the company said it received a patent for its in-development treatment for opioid use disorder.The stock jumped 32%, to $2.73, in after-hours trading. Through Tuesday's regular session, shares have lost three-quarters of their value in the past year.The pharmaceutical company's chief executive, Lynn Kirkpatrick, said after the bell that Ensysce made strides during the recent quarter to deliver what the company believes are next-generation opioid analgesics, which protect against both abuse and overdose.Recent achievements, she said, include the receipt of a notice of allowance from the U.S. Patent and Trademark Office for the company's lead opioid-use-disorder drug candidate, PF9001. The drug is designed to have several advantages over current methadone therapy such as reduced cardiotoxicity, she added.Kirkpatrick noted that the company continues to work on the development of its lead product, PF614, an extended-release oxycodone to treat sev","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ensysce Biosciences Shares Jump After Receiving Patent, Reporting 1Q Results","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2535500087","title":"Ensysce Biosciences Q1 EPS $(1.39) Beats $(3.02) Estimate, Sales $1.32M Up From $305.72K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535500087","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535500087?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:39","pubTimestamp":1747168757,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.39) per share which beat the analyst consensus estimate of $(3.02) by 53.97 percent. This is a 83.07 percent increase over losses of $(8.21) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45391889/ensysce-biosciences-q1-eps-1-39-beats-3-02-estimate-sales-1-32m-up-from-305-72k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENSC"],"gpt_icon":0},{"id":"2532100874","title":"Ensysce Biosciences files to sell 1.3M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2532100874","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532100874?lang=en_us&edition=fundamental","pubTime":"2025-05-03 04:40","pubTimestamp":1746218412,"startTime":"0","endTime":"0","summary":"16:39 EDT Ensysce Biosciences (ENSC) files to sell 1.3M shares of common stock for holders Published first on TheFly – the ultimate source for real...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-files-to-sell-1-3m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-files-to-sell-1-3m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2529669985","title":"Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2529669985","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529669985?lang=en_us&edition=fundamental","pubTime":"2025-04-24 05:11","pubTimestamp":1745442703,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences, Inc  stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as per data from Benzinga Pro.Ensysce Biosciences on Wednesday received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitledEnzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof including both composition of matter and method of use claims.PF9001, the medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder  by using Ensysce’s TAAPand MPARabuse-deterrent and overdose protection technologies.Ensysce Biosciences completed Part 1 of its second clinical trial in April to evaluate PF614-MPAR for overdose protection.PF614-MPAR-102 demonstrated that the combined Ensysce TAAPand MPARtechnologies can relieve severe pain yet protect from the risk of excessive doses when consumed accidentally or deliberately.Part 1 of this second study of PF614-MPAR overdose protection c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-stock-doubles-one-211143048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2529669604","title":"Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2529669604","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529669604?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:41","pubTimestamp":1745440860,"startTime":"0","endTime":"0","summary":"SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc.  , a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 630,376 shares of common stock of the Company originally issued in March 2025, having an exercise price of $3.24 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 . The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.2 million, prior to deducting placement agent fees and estimated offering expenses.This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-inc-announces-exercise-204100863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2529582506","title":"Crude Oil Falls Over 3%; Philip Morris Earnings Top Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2529582506","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529582506?lang=en_us&edition=fundamental","pubTime":"2025-04-24 00:56","pubTimestamp":1745427366,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44958263/crude-oil-falls-over-3-philip-morris-earnings-top-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNOA","ENSC","PM","CHKP","ENPH","CTHR"],"gpt_icon":1},{"id":"2529688888","title":"Ensysce Biosciences Gets US Patent for Opioid Use Disorder Treatment; Shares Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2529688888","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529688888?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:45","pubTimestamp":1745412300,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences  said Wednesday it has received a notice of allowance for PF9001, a medication for treating opioid use disorder, from the US Patent and Trademark Office.Data showed that the medication reduced the potential for cardiotoxicity and could potentially deliver a prolonged and predictable effect on daily dosing, the biotechnology company said.Shares were over 125% higher in recent premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2529500919","title":"Ensysce Biosciences receives U.S. patent for OUD treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529500919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529500919?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:36","pubTimestamp":1745411767,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences (ENSC) received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled: Enzyme-C...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-receives-u-s-patent-for-oud-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-receives-u-s-patent-for-oud-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENSC","BK4139"],"gpt_icon":0},{"id":"2529504774","title":"Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2529504774","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529504774?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~~ Prioritizes Safety and Tolerability for OUD Patients ~Methadone has long been a cornerstone treatment for OUD, but its use has been limited by concerns over cardiac side effects, respiratory depression, and risk of overdose. Ensysce has developed a new class of agents for the treatment for OUD in the form of PF9001. This new drug is a significant advancement in the treatment of OUD, with data demonstrating a reduction in potential for cardiotoxicity, validating MPAR overdose protection, and indications of potentially delivering a prolonged and predictable effect following once daily dosing.About Ensysce BiosciencesEnsysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection  and Multi-Pill Abuse Resistance  platforms, the Company is developing uniq","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ensysce-biosciences-receives-u-patent-120000225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENSC"],"gpt_icon":0},{"id":"2528085292","title":"Ensysce Biosciences files to sell 652,439 shares of common Stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2528085292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528085292?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:35","pubTimestamp":1744835745,"startTime":"0","endTime":"0","summary":"16:33 EDT Ensysce Biosciences (ENSC) files to sell 652,439 shares of common Stock for holders Published first on TheFly – the ultimate source for r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-files-to-sell-652439-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ensysce-biosciences-files-to-sell-652439-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENSC"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENSC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"ENSC","fiscalQuarterEnding":"2025/03","expectedEps":-3.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-1.39},{"market":"US","date":"2025-03-10","symbol":"ENSC","fiscalQuarterEnding":"2024/12","expectedEps":-2.74,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741579200000,"reportTimeType":"post","actualEps":-2.9},{"market":"US","date":"2024-12-06","symbol":"ENSC","defaultRemindTime":1733495400000,"type":"split","dateTimestamp":1733461200000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-12","symbol":"ENSC","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-08-14","symbol":"ENSC","fiscalQuarterEnding":"2024/06","expectedEps":-0.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENSC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENSC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENSC","date":"2025-07-31","current":-0.723481,"percent":0.304523,"low":-1151.871294,"twenty":-1.17593,"median":-0.402877,"eighty":-0.220251,"high":2051.953734,"avg":-9.895438,"sd":290.619598,"marketCap":4931051},"quantilePoints":[{"date":"2021-07-02","current":2051.953734,"twenty":2050.538593,"median":2050.538593,"eighty":2051.387678,"marketCap":353522901},{"date":"2021-07-09","current":1665.538105,"twenty":1670.376702,"median":2037.802329,"eighty":2050.538593,"marketCap":286948898},{"date":"2021-07-16","current":1373.799461,"twenty":1582.794518,"median":1666.827366,"eighty":2047.99134,"marketCap":236686414},{"date":"2021-07-23","current":986.303472,"twenty":1176.265418,"median":1592.804232,"eighty":1966.125264,"marketCap":169926280},{"date":"2021-07-30","current":796.099172,"twenty":905.447974,"median":1416.070215,"eighty":1677.156928,"marketCap":137156742},{"date":"2021-08-06","current":598.835663,"twenty":785.954194,"median":1130.038123,"eighty":1667.600922,"marketCap":103171001},{"date":"2021-08-13","current":462.160228,"twenty":607.289814,"median":986.310516,"eighty":1664.774414,"marketCap":79623737},{"date":"2021-08-20","current":-800.661067,"twenty":514.012352,"median":880.640679,"eighty":1647.936568,"marketCap":79073287},{"date":"2021-08-27","current":-761.364824,"twenty":-747.61113,"median":789.758561,"eighty":1590.301804,"marketCap":75192390},{"date":"2021-09-03","current":-825.221223,"twenty":-767.750462,"median":676.332041,"eighty":1555.901866,"marketCap":81498848},{"date":"2021-09-10","current":-859.605437,"twenty":-780.52174,"median":598.835663,"eighty":1458.340968,"marketCap":84894633},{"date":"2021-09-17","current":-724.524585,"twenty":-780.52174,"median":555.860395,"eighty":1373.799461,"marketCap":71554048},{"date":"2021-09-24","current":-1102.750982,"twenty":-800.661067,"median":488.931707,"eighty":1361.174599,"marketCap":108907687},{"date":"2021-10-01","current":-704.876458,"twenty":-815.397165,"median":-708.560485,"eighty":1130.038123,"marketCap":69613599},{"date":"2021-10-08","current":-582.075678,"twenty":-800.661067,"median":-611.547874,"eighty":1000.40781,"marketCap":57485794},{"date":"2021-10-15","current":-582.075678,"twenty":-788.380994,"median":-604.17982,"eighty":986.317559,"marketCap":57485794},{"date":"2021-10-22","current":-547.691464,"twenty":-781.01294,"median":-601.723805,"eighty":986.303472,"marketCap":54090009},{"date":"2021-10-29","current":-540.32342,"twenty":-780.52174,"median":-596.811776,"eighty":885.234099,"marketCap":53362341},{"date":"2021-11-05","current":-552.603493,"twenty":-778.556926,"median":-582.075678,"eighty":880.640679,"marketCap":54575121},{"date":"2021-11-12","current":-542.779435,"twenty":-776.100911,"median":-575.935642,"eighty":879.231656,"marketCap":53604897},{"date":"2021-11-19","current":-2.041392,"twenty":-776.100911,"median":-559.971547,"eighty":796.099172,"marketCap":38445141},{"date":"2021-11-26","current":-2.034952,"twenty":-774.1361,"median":-555.059508,"eighty":785.954194,"marketCap":38323863},{"date":"2021-12-03","current":-1.609931,"twenty":-769.715274,"median":-550.147479,"eighty":769.891308,"marketCap":30319512},{"date":"2021-12-10","current":-5.705594,"twenty":-764.803244,"median":-542.779435,"eighty":694.367562,"marketCap":107452350},{"date":"2021-12-17","current":-3.812316,"twenty":-763.820838,"median":-539.095413,"eighty":648.151541,"marketCap":71796604},{"date":"2021-12-23","current":-6.594276,"twenty":-762.34723,"median":-537.867406,"eighty":615.743964,"marketCap":124188721},{"date":"2021-12-31","current":-6.053339,"twenty":-758.417601,"median":-6.594276,"eighty":588.690681,"marketCap":114001365},{"date":"2022-01-07","current":-5.138899,"twenty":-754.979176,"median":-6.175695,"eighty":578.5457,"marketCap":96779882},{"date":"2022-01-14","current":-4.224458,"twenty":-753.99677,"median":-5.705594,"eighty":551.774222,"marketCap":79558399},{"date":"2022-01-21","current":-3.078187,"twenty":-753.99677,"median":-5.692715,"eighty":524.720941,"marketCap":57970907},{"date":"2022-01-28","current":-2.150867,"twenty":-750.067147,"median":-5.409367,"eighty":500.767517,"marketCap":40506868},{"date":"2022-02-04","current":-2.073591,"twenty":-736.313461,"median":-5.254814,"eighty":478.223115,"marketCap":39051531},{"date":"2022-02-11","current":-2.073591,"twenty":-719.612556,"median":-4.939267,"eighty":276.652164,"marketCap":39051531},{"date":"2022-02-18","current":-1.39742,"twenty":-709.29729,"median":-4.623721,"eighty":-1.482424,"marketCap":26317336},{"date":"2022-02-25","current":-1.40386,"twenty":-687.68435,"median":-4.456288,"eighty":-1.367797,"marketCap":26438614},{"date":"2022-03-04","current":-1.378101,"twenty":-617.442308,"median":-4.218019,"eighty":-1.378101,"marketCap":25953502},{"date":"2022-03-11","current":-1.416739,"twenty":-611.056671,"median":-4.17294,"eighty":-1.367797,"marketCap":26681170},{"date":"2022-03-18","current":-1.584172,"twenty":-608.600654,"median":-3.915351,"eighty":-1.367797,"marketCap":29834399},{"date":"2022-03-25","current":-1.455377,"twenty":-606.635834,"median":-3.72216,"eighty":-1.378101,"marketCap":27408838},{"date":"2022-04-01","current":-0.909052,"twenty":-605.653428,"median":-3.026669,"eighty":-1.367797,"marketCap":26438614},{"date":"2022-04-08","current":-0.942412,"twenty":-601.723805,"median":-2.640286,"eighty":-1.243923,"marketCap":27408838},{"date":"2022-04-14","current":-0.892372,"twenty":-601.723805,"median":-2.31186,"eighty":-1.109211,"marketCap":25953502},{"date":"2022-04-22","current":-0.884033,"twenty":-599.267791,"median":-2.221704,"eighty":-0.942412,"marketCap":25710946},{"date":"2022-04-29","current":-0.917392,"twenty":-599.267791,"median":-2.189506,"eighty":-0.917392,"marketCap":26681170},{"date":"2022-05-06","current":-0.935552,"twenty":-594.355761,"median":-2.131548,"eighty":-0.917392,"marketCap":27209326},{"date":"2022-05-13","current":-0.797005,"twenty":-582.075678,"median":-2.08647,"eighty":-0.892372,"marketCap":23214444},{"date":"2022-05-20","current":-0.624837,"twenty":-582.075678,"median":-2.073591,"eighty":-0.867353,"marketCap":18199682},{"date":"2022-05-27","current":-0.62899,"twenty":-582.075678,"median":-2.041392,"eighty":-0.82967,"marketCap":18320644},{"date":"2022-06-03","current":-0.645958,"twenty":-578.146055,"median":-2.034952,"eighty":-0.778733,"marketCap":18814863},{"date":"2022-06-10","current":-0.587461,"twenty":-575.198838,"median":-1.960895,"eighty":-0.698325,"marketCap":17111019},{"date":"2022-06-17","current":-0.537744,"twenty":-566.848388,"median":-1.931917,"eighty":-0.663661,"marketCap":15662924},{"date":"2022-06-24","current":-0.547118,"twenty":-561.936359,"median":-1.803122,"eighty":-0.641971,"marketCap":15935954},{"date":"2022-07-01","current":-0.675147,"twenty":-559.971547,"median":-1.758044,"eighty":-0.628942,"marketCap":19665057},{"date":"2022-07-08","current":-0.740288,"twenty":-558.006731,"median":-1.63569,"eighty":-0.63179,"marketCap":21562441},{"date":"2022-07-15","current":-0.73318,"twenty":-554.077102,"median":-1.584172,"eighty":-0.639978,"marketCap":21355409},{"date":"2022-07-22","current":-0.750097,"twenty":-552.603493,"median":-1.526215,"eighty":-0.650372,"marketCap":21848142},{"date":"2022-07-29","current":-0.645214,"twenty":-550.638681,"median":-1.455377,"eighty":-0.648267,"marketCap":18793198},{"date":"2022-08-05","current":-0.542837,"twenty":-547.691464,"median":-1.436058,"eighty":-0.628919,"marketCap":15811251},{"date":"2022-08-12","current":-0.502219,"twenty":-545.726652,"median":-1.416739,"eighty":-0.623627,"marketCap":18104172},{"date":"2022-08-19","current":-0.4432,"twenty":-541.797029,"median":-1.400842,"eighty":-0.597747,"marketCap":15976634},{"date":"2022-08-26","current":-0.437558,"twenty":-540.32342,"median":-1.39098,"eighty":-0.585573,"marketCap":15773232},{"date":"2022-09-02","current":-0.436493,"twenty":-539.341014,"median":-1.39098,"eighty":-0.574176,"marketCap":15734855},{"date":"2022-09-09","current":-0.364844,"twenty":-537.867406,"median":-1.38776,"eighty":-0.560252,"marketCap":13152036},{"date":"2022-09-16","current":-0.333012,"twenty":-537.867406,"median":-1.378101,"eighty":-0.543432,"marketCap":12004543},{"date":"2022-09-23","current":-0.234109,"twenty":-537.376203,"median":-1.352342,"eighty":-0.508327,"marketCap":8439255},{"date":"2022-09-30","current":-0.228893,"twenty":-429.647968,"median":-1.243734,"eighty":-0.498322,"marketCap":8251204},{"date":"2022-10-07","current":-0.234216,"twenty":-6.555638,"median":-1.18844,"eighty":-0.457146,"marketCap":8443092},{"date":"2022-10-14","current":-0.220376,"twenty":-6.367598,"median":-1.109211,"eighty":-0.440474,"marketCap":7944182},{"date":"2022-10-21","current":-0.210262,"twenty":-6.210469,"median":-1.003086,"eighty":-0.435641,"marketCap":7579594},{"date":"2022-10-28","current":-0.250893,"twenty":-6.104857,"median":-0.950752,"eighty":-0.392333,"marketCap":9044283},{"date":"2022-11-04","current":-0.17653,"twenty":-5.98379,"median":-0.934812,"eighty":-0.354113,"marketCap":6363632},{"date":"2022-11-11","current":-0.1248,"twenty":-5.705594,"median":-0.917392,"eighty":-0.266963,"marketCap":4498831},{"date":"2022-11-18","current":-0.202801,"twenty":-5.703018,"median":-0.904882,"eighty":-0.252442,"marketCap":5824224},{"date":"2022-11-25","current":-0.338332,"twenty":-5.692715,"median":-0.892372,"eighty":-0.252314,"marketCap":9716511},{"date":"2022-12-02","current":-0.220875,"twenty":-5.666956,"median":-0.884033,"eighty":-0.252314,"marketCap":6343293},{"date":"2022-12-09","current":-0.218547,"twenty":-5.525282,"median":-0.867353,"eighty":-0.245714,"marketCap":6276429},{"date":"2022-12-16","current":-0.173271,"twenty":-5.293452,"median":-0.82967,"eighty":-0.238048,"marketCap":4976162},{"date":"2022-12-23","current":-0.160808,"twenty":-5.254814,"median":-0.801912,"eighty":-0.234216,"marketCap":4618230},{"date":"2022-12-30","current":-0.167485,"twenty":-5.254814,"median":-0.794791,"eighty":-0.233587,"marketCap":4809988},{"date":"2023-01-06","current":-0.162144,"twenty":-5.208448,"median":-0.777262,"eighty":-0.229014,"marketCap":4656609},{"date":"2023-01-13","current":-0.172083,"twenty":-5.154354,"median":-0.761172,"eighty":-0.22176,"marketCap":4942034},{"date":"2023-01-20","current":-0.151312,"twenty":-4.979194,"median":-0.754483,"eighty":-0.220248,"marketCap":4345527},{"date":"2023-01-27","current":-0.15636,"twenty":-4.713877,"median":-0.749721,"eighty":-0.212142,"marketCap":4490485},{"date":"2023-02-03","current":-0.285115,"twenty":-4.654632,"median":-0.740288,"eighty":-0.212142,"marketCap":8188175},{"date":"2023-02-10","current":-0.319777,"twenty":-4.577355,"median":-0.716973,"eighty":-0.2146,"marketCap":9183632},{"date":"2023-02-17","current":-0.306121,"twenty":-4.487199,"median":-0.704416,"eighty":-0.217004,"marketCap":8791464},{"date":"2023-02-24","current":-0.268404,"twenty":-4.453712,"median":-0.69164,"eighty":-0.21887,"marketCap":7708271},{"date":"2023-03-03","current":-0.278653,"twenty":-4.399619,"median":-0.674554,"eighty":-0.220206,"marketCap":8002622},{"date":"2023-03-10","current":-0.295605,"twenty":-4.221882,"median":-0.670756,"eighty":-0.220476,"marketCap":8489450},{"date":"2023-03-17","current":-0.319044,"twenty":-4.206427,"median":-0.666784,"eighty":-0.220988,"marketCap":9162596},{"date":"2023-03-24","current":-0.28195,"twenty":-4.183244,"median":-0.656993,"eighty":-0.221547,"marketCap":8097283},{"date":"2023-03-31","current":-0.251749,"twenty":-4.160061,"median":-0.645586,"eighty":-0.223101,"marketCap":6085356},{"date":"2023-04-06","current":-0.180809,"twenty":-4.108543,"median":-0.632491,"eighty":-0.22144,"marketCap":4370577},{"date":"2023-04-14","current":-0.203676,"twenty":-3.992628,"median":-0.624837,"eighty":-0.218547,"marketCap":4923327},{"date":"2023-04-21","current":-0.218035,"twenty":-3.838075,"median":-0.616531,"eighty":-0.218035,"marketCap":5270402},{"date":"2023-04-28","current":-0.207399,"twenty":-3.812316,"median":-0.595341,"eighty":-0.211114,"marketCap":5013309},{"date":"2023-05-05","current":-0.186,"twenty":-3.72216,"median":-0.589774,"eighty":-0.207399,"marketCap":4496040},{"date":"2023-05-12","current":-0.170057,"twenty":-3.593365,"median":-0.578926,"eighty":-0.203676,"marketCap":4110665},{"date":"2023-05-19","current":-0.138524,"twenty":-3.078187,"median":-0.574237,"eighty":-0.198975,"marketCap":3519757},{"date":"2023-05-26","current":-0.119818,"twenty":-2.975152,"median":-0.564854,"eighty":-0.195168,"marketCap":3044461},{"date":"2023-06-02","current":-0.12184,"twenty":-2.799991,"median":-0.554475,"eighty":-0.191738,"marketCap":3095845},{"date":"2023-06-09","current":-0.11729,"twenty":-2.663469,"median":-0.544325,"eighty":-0.188162,"marketCap":2980232},{"date":"2023-06-16","current":-0.120324,"twenty":-2.403304,"median":-0.537744,"eighty":-0.185529,"marketCap":3057307},{"date":"2023-06-22","current":-0.110212,"twenty":-2.331179,"median":-0.512831,"eighty":-0.181667,"marketCap":2800390},{"date":"2023-06-30","current":-0.089484,"twenty":-2.31186,"median":-0.504284,"eighty":-0.180301,"marketCap":2273711},{"date":"2023-07-07","current":-0.108696,"twenty":-2.269358,"median":-0.500344,"eighty":-0.179074,"marketCap":2761853},{"date":"2023-07-14","current":-0.095551,"twenty":-2.235871,"median":-0.48602,"eighty":-0.176463,"marketCap":2427861},{"date":"2023-07-21","current":-0.228917,"twenty":-2.222992,"median":-0.463108,"eighty":-0.17453,"marketCap":5816563},{"date":"2023-07-28","current":-0.230007,"twenty":-2.204961,"median":-0.448416,"eighty":-0.176463,"marketCap":5844261},{"date":"2023-08-04","current":-0.212566,"twenty":-2.189506,"median":-0.439793,"eighty":-0.177048,"marketCap":5401094},{"date":"2023-08-11","current":-0.213656,"twenty":-2.17405,"median":-0.436546,"eighty":-0.178163,"marketCap":5428792},{"date":"2023-08-18","current":-0.284273,"twenty":-2.145715,"median":-0.431596,"eighty":-0.17894,"marketCap":5612832},{"date":"2023-08-25","current":-0.281373,"twenty":-2.132836,"median":-0.405938,"eighty":-0.179667,"marketCap":5555558},{"date":"2023-09-01","current":-0.268319,"twenty":-2.119956,"median":-0.373875,"eighty":-0.180213,"marketCap":5297826},{"date":"2023-09-08","current":-0.274121,"twenty":-2.107077,"median":-0.367186,"eighty":-0.180403,"marketCap":5412374},{"date":"2023-09-15","current":-0.255266,"twenty":-2.08647,"median":-0.356221,"eighty":-0.180828,"marketCap":5040094},{"date":"2023-09-22","current":-0.23061,"twenty":-2.083894,"median":-0.35054,"eighty":-0.181286,"marketCap":4553267},{"date":"2023-09-29","current":-0.197251,"twenty":-2.073591,"median":-0.336589,"eighty":-0.182977,"marketCap":3894618},{"date":"2023-10-06","current":-0.159541,"twenty":-2.068439,"median":-0.324381,"eighty":-0.181273,"marketCap":3150059},{"date":"2023-10-12","current":-0.175495,"twenty":-2.047832,"median":-0.319777,"eighty":-0.180154,"marketCap":3465064},{"date":"2023-10-20","current":-0.224808,"twenty":-2.041392,"median":-0.319097,"eighty":-0.180301,"marketCap":4438719},{"date":"2023-10-27","current":-0.15519,"twenty":-2.038816,"median":-0.31805,"eighty":-0.180213,"marketCap":3064148},{"date":"2023-11-03","current":-0.147166,"twenty":-2.034952,"median":-0.312913,"eighty":-0.177994,"marketCap":2905715},{"date":"2023-11-10","current":-0.135455,"twenty":-2.034952,"median":-0.311621,"eighty":-0.175524,"marketCap":2674479},{"date":"2023-11-17","current":-0.234708,"twenty":-2.022073,"median":-0.305807,"eighty":-0.175796,"marketCap":2957311},{"date":"2023-11-24","current":-0.219726,"twenty":-1.970555,"median":-0.300549,"eighty":-0.176418,"marketCap":2768546},{"date":"2023-12-01","current":-0.284645,"twenty":-1.951236,"median":-0.295186,"eighty":-0.17653,"marketCap":3586526},{"date":"2023-12-08","current":-0.245519,"twenty":-1.931917,"median":-0.292717,"eighty":-0.177824,"marketCap":3093536},{"date":"2023-12-15","current":-0.25718,"twenty":-1.931917,"median":-0.287495,"eighty":-0.178672,"marketCap":3240458},{"date":"2023-12-22","current":-0.26467,"twenty":-1.893278,"median":-0.287174,"eighty":-0.179342,"marketCap":3334840},{"date":"2023-12-29","current":-0.25718,"twenty":-1.839184,"median":-0.286889,"eighty":-0.179829,"marketCap":3240458},{"date":"2024-01-05","current":-0.287142,"twenty":-1.800546,"median":-0.286002,"eighty":-0.180183,"marketCap":3617987},{"date":"2024-01-12","current":-0.352061,"twenty":-1.787667,"median":-0.286889,"eighty":-0.180403,"marketCap":4435967},{"date":"2024-01-19","current":-0.29713,"twenty":-1.777363,"median":-0.287142,"eighty":-0.180809,"marketCap":3743830},{"date":"2024-01-26","current":-0.374533,"twenty":-1.738725,"median":-0.287142,"eighty":-0.180905,"marketCap":4719114},{"date":"2024-02-02","current":-0.36954,"twenty":-1.648569,"median":-0.287174,"eighty":-0.181297,"marketCap":4656192},{"date":"2024-02-09","current":-0.294633,"twenty":-1.62281,"median":-0.290994,"eighty":-0.182747,"marketCap":3712369},{"date":"2024-02-16","current":-0.476633,"twenty":-1.609931,"median":-0.289857,"eighty":-0.182811,"marketCap":6005566},{"date":"2024-02-23","current":-0.47931,"twenty":-1.589324,"median":-0.293303,"eighty":-0.183477,"marketCap":6039299},{"date":"2024-03-01","current":-0.49934,"twenty":-1.563565,"median":-0.295134,"eighty":-0.185529,"marketCap":6291674},{"date":"2024-03-08","current":-0.420937,"twenty":-1.537806,"median":-0.29713,"eighty":-0.187269,"marketCap":5303792},{"date":"2024-03-15","current":-0.401657,"twenty":-1.522351,"median":-0.301226,"eighty":-0.187592,"marketCap":5060871},{"date":"2024-03-22","current":-0.539343,"twenty":-1.509471,"median":-0.306121,"eighty":-0.187752,"marketCap":5724083},{"date":"2024-03-28","current":-0.552464,"twenty":-1.475984,"median":-0.311621,"eighty":-0.188069,"marketCap":5863337},{"date":"2024-04-05","current":-0.582158,"twenty":-1.455377,"median":-0.312913,"eighty":-0.188946,"marketCap":6178491},{"date":"2024-04-12","current":-0.520524,"twenty":-1.44765,"median":-0.317056,"eighty":-0.189992,"marketCap":5524363},{"date":"2024-04-19","current":-0.400674,"twenty":-1.43477,"median":-0.319149,"eighty":-0.190623,"marketCap":4252385},{"date":"2024-04-26","current":-0.390727,"twenty":-1.426836,"median":-0.324381,"eighty":-0.191499,"marketCap":4146813},{"date":"2024-05-03","current":-0.406665,"twenty":-1.420036,"median":-0.328965,"eighty":-0.192296,"marketCap":4315962},{"date":"2024-05-10","current":-0.38701,"twenty":-1.416739,"median":-0.333012,"eighty":-0.192744,"marketCap":4107370},{"date":"2024-05-17","current":-0.414034,"twenty":-1.409012,"median":-0.340203,"eighty":-0.194261,"marketCap":4778658},{"date":"2024-05-24","current":-0.386958,"twenty":-1.400239,"median":-0.345309,"eighty":-0.195168,"marketCap":4466149},{"date":"2024-05-31","current":-0.38446,"twenty":-1.397663,"median":-0.35054,"eighty":-0.195327,"marketCap":4437325},{"date":"2024-06-07","current":-0.35929,"twenty":-1.394844,"median":-0.352061,"eighty":-0.195908,"marketCap":4146813},{"date":"2024-06-14","current":-0.348315,"twenty":-1.39098,"median":-0.352127,"eighty":-0.196588,"marketCap":4020141},{"date":"2024-06-21","current":-0.358489,"twenty":-1.39098,"median":-0.352127,"eighty":-0.197251,"marketCap":4137567},{"date":"2024-06-28","current":-0.352192,"twenty":-1.39098,"median":-0.352192,"eighty":-0.197427,"marketCap":4064893},{"date":"2024-07-05","current":-0.295739,"twenty":-1.39098,"median":-0.352061,"eighty":-0.197948,"marketCap":3413327},{"date":"2024-07-12","current":-0.308291,"twenty":-1.39098,"median":-0.35054,"eighty":-0.199037,"marketCap":3558204},{"date":"2024-07-15","current":-0.302639,"twenty":-1.39098,"median":-0.349428,"eighty":-0.199099,"marketCap":3492971},{"date":"2024-08-02","current":-0.303954,"twenty":-1.39098,"median":-0.348315,"eighty":-0.199161,"marketCap":3508142},{"date":"2024-08-09","current":-0.241717,"twenty":-1.387116,"median":-0.345859,"eighty":-0.199565,"marketCap":2789826},{"date":"2024-08-16","current":-0.26447,"twenty":-1.380677,"median":-0.342074,"eighty":-0.199992,"marketCap":2982489},{"date":"2024-08-23","current":-0.307981,"twenty":-1.378101,"median":-0.336589,"eighty":-0.20065,"marketCap":3473180},{"date":"2024-08-30","current":-0.307305,"twenty":-1.370373,"median":-0.334845,"eighty":-0.202073,"marketCap":3465556},{"date":"2024-09-06","current":-0.364516,"twenty":-1.360069,"median":-0.341743,"eighty":-0.202979,"marketCap":4110738},{"date":"2024-09-13","current":-0.306193,"twenty":-1.352342,"median":-0.340037,"eighty":-0.203419,"marketCap":3453020},{"date":"2024-09-20","current":-0.321066,"twenty":-1.320968,"median":-0.335355,"eighty":-0.203676,"marketCap":3620738},{"date":"2024-09-27","current":-0.26527,"twenty":-1.261837,"median":-0.332941,"eighty":-0.20384,"marketCap":2991521},{"date":"2024-10-04","current":-0.225611,"twenty":-1.240811,"median":-0.332086,"eighty":-0.204208,"marketCap":2544273},{"date":"2024-10-11","current":-0.228772,"twenty":-1.222236,"median":-0.329966,"eighty":-0.204208,"marketCap":2579914},{"date":"2024-10-18","current":-0.220531,"twenty":-1.190942,"median":-0.325844,"eighty":-0.204432,"marketCap":2486982},{"date":"2024-10-25","current":-0.387436,"twenty":-1.154623,"median":-0.327156,"eighty":-0.205107,"marketCap":4369210},{"date":"2024-10-31","current":-0.78508,"twenty":-1.119973,"median":-0.329966,"eighty":-0.206243,"marketCap":8853546},{"date":"2024-11-08","current":-0.85568,"twenty":-1.097263,"median":-0.332086,"eighty":-0.207117,"marketCap":9649713},{"date":"2024-11-15","current":-1.112489,"twenty":-1.111833,"median":-0.332941,"eighty":-0.207179,"marketCap":8817483},{"date":"2024-11-22","current":-1.463005,"twenty":-1.187197,"median":-0.335355,"eighty":-0.2074,"marketCap":11595645},{"date":"2024-11-29","current":-1.219747,"twenty":-1.20095,"median":-0.339535,"eighty":-0.207404,"marketCap":9667605},{"date":"2024-12-06","current":-1.19258,"twenty":-1.236427,"median":-0.343222,"eighty":-0.208116,"marketCap":9452284},{"date":"2024-12-13","current":-1.007606,"twenty":-1.236427,"median":-0.346409,"eighty":-0.208205,"marketCap":7986196},{"date":"2024-12-20","current":-1.3089,"twenty":-1.236427,"median":-0.348396,"eighty":-0.208854,"marketCap":10374225},{"date":"2024-12-27","current":-1.541045,"twenty":-1.25409,"median":-0.351152,"eighty":-0.20886,"marketCap":12214182},{"date":"2025-01-03","current":-1.358293,"twenty":-1.336231,"median":-0.352061,"eighty":-0.209,"marketCap":10765705},{"date":"2025-01-10","current":-1.303961,"twenty":-1.349402,"median":-0.352192,"eighty":-0.209431,"marketCap":10335077},{"date":"2025-01-17","current":-1.152491,"twenty":-1.345121,"median":-0.352708,"eighty":-0.209959,"marketCap":9134538},{"date":"2025-01-24","current":-1.307254,"twenty":-1.346768,"median":-0.358489,"eighty":-0.210043,"marketCap":10361175},{"date":"2025-01-31","current":-1.104745,"twenty":-1.338865,"median":-0.359421,"eighty":-0.21027,"marketCap":8756107},{"date":"2025-02-07","current":-1.053706,"twenty":-1.330304,"median":-0.362904,"eighty":-0.210466,"marketCap":8351577},{"date":"2025-02-14","current":-0.996081,"twenty":-1.315486,"median":-0.36403,"eighty":-0.21134,"marketCap":7894850},{"date":"2025-02-21","current":-0.926932,"twenty":-1.3089,"median":-0.364942,"eighty":-0.212244,"marketCap":7346778},{"date":"2025-02-28","current":-0.864368,"twenty":-1.307254,"median":-0.367373,"eighty":-0.212536,"marketCap":6850903},{"date":"2025-03-07","current":-0.856136,"twenty":-1.303961,"median":-0.371707,"eighty":-0.212566,"marketCap":6785656},{"date":"2025-03-14","current":-0.637359,"twenty":-1.279265,"median":-0.374533,"eighty":-0.212566,"marketCap":5090547},{"date":"2025-03-21","current":-0.626307,"twenty":-1.273906,"median":-0.375127,"eighty":-0.213521,"marketCap":5002277},{"date":"2025-03-28","current":-0.548899,"twenty":-1.249136,"median":-0.377888,"eighty":-0.213656,"marketCap":4384018},{"date":"2025-04-04","current":-0.402877,"twenty":-1.247983,"median":-0.38361,"eighty":-0.213683,"marketCap":3217756},{"date":"2025-04-11","current":-0.330747,"twenty":-1.243734,"median":-0.377888,"eighty":-0.213752,"marketCap":2641651},{"date":"2025-04-17","current":-0.330747,"twenty":-1.241359,"median":-0.377888,"eighty":-0.214536,"marketCap":2641651},{"date":"2025-04-25","current":-0.582325,"twenty":-1.237295,"median":-0.37685,"eighty":-0.214732,"marketCap":4650993},{"date":"2025-05-02","current":-0.522509,"twenty":-1.233817,"median":-0.383262,"eighty":-0.215726,"marketCap":4173247},{"date":"2025-05-09","current":-0.365932,"twenty":-1.222431,"median":-0.382514,"eighty":-0.21608,"marketCap":2922678},{"date":"2025-05-16","current":-0.441183,"twenty":-1.219747,"median":-0.383262,"eighty":-0.217023,"marketCap":3006986},{"date":"2025-05-23","current":-0.447368,"twenty":-1.206773,"median":-0.38446,"eighty":-0.217878,"marketCap":3049140},{"date":"2025-05-30","current":-0.451491,"twenty":-1.201982,"median":-0.384903,"eighty":-0.218264,"marketCap":3077243},{"date":"2025-06-06","current":-0.564674,"twenty":-1.195928,"median":-0.386958,"eighty":-0.218495,"marketCap":3848663},{"date":"2025-06-13","current":-0.516411,"twenty":-1.19104,"median":-0.388248,"eighty":-0.21863,"marketCap":3519717},{"date":"2025-06-20","current":-0.513998,"twenty":-1.188835,"median":-0.39137,"eighty":-0.218686,"marketCap":3503270},{"date":"2025-06-27","current":-0.535716,"twenty":-1.185222,"median":-0.394081,"eighty":-0.219102,"marketCap":3651296},{"date":"2025-07-03","current":-0.557434,"twenty":-1.182061,"median":-0.399017,"eighty":-0.219726,"marketCap":3799321},{"date":"2025-07-11","current":-0.504345,"twenty":-1.180151,"median":-0.399987,"eighty":-0.219813,"marketCap":3437481},{"date":"2025-07-18","current":-0.751307,"twenty":-1.178504,"median":-0.401019,"eighty":-0.22017,"marketCap":5120707},{"date":"2025-07-25","current":-0.76522,"twenty":-1.176936,"median":-0.401964,"eighty":-0.220207,"marketCap":5215535},{"date":"2025-07-31","current":-0.723481,"twenty":-1.17593,"median":-0.402877,"eighty":-0.220251,"marketCap":4931051}],"updateTime":1754092316390}}}